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Popliteal Artery Aneurysm Repair in the Endovascular Era
Fourteen-Years Single Center Experience
Sonia Ronchey, MD, Felice Pecoraro, MD, Vittorio Alberti, MD, Eugenia Serrao, MD,
Matteo Orrico, MD, Mario Lachat, MD, and Nicola Mangialardi, MD
Abstract: To compare outcomes of popliteal artery aneurysm (PAA)
repair by endovascular treatment, great saphenous vein (GSV) bypass,
and prosthetic bypass.
Single center retrospective analysis of patients presenting PAA from
2000 to 2013. Patients were divided into endovascular treatment (group
A); GSV bypass (group B); and prosthetic graft bypass (group C).
Outcomes were technical success, perioperative mortality, and morbidity.
Survival, primary and secondary patency, and freedom from reinterven-
tion rate were estimated. Differences in ankle-brachial index (ABI),
in-hospital length of stay (InH-Los), red blood cell (RBC) transfusion,
and limb loss were reported. Mean follow-up was 49 (median: 35; 1–145;
SD 42) months.
Sixty-seven patients were included; 25 in group A, 28 in group B, and
14 in group C. PAA was symptomatic in 23 (34%) cases. Technical
success was 100%. No perioperative death occurred. Three (4.5%)
perioperative complications were reported with no significant difference
between groups (P¼0.866). Five-years estimated survival was 78%.
Estimated 5-years primary patency for groups A, B, and C was 71%,
81%, and 69%, respectively (P¼0.19). Estimated 5-years secondary
patency for groups A, B, and C was 88%, 85%, and 84% (P¼0.85).
Estimated 5-years freedom from reintervention for groups A, B, and C
was 62%, 84%, and 70%, respectively (P¼0.16). A significant differ-
ence between preoperative ABI versus postoperative ABI was observed
(P¼0.001). InH-LoS was significantly shorter in group A (P<0.001).
RBC transfusions were required significantly less in group A when
compared to group C (P¼0.045). Overall limb salvage was achieved
in all but 1 patient.
PAA repair has good early and long-term outcomes with different
treatment options. Endovascular treatment was not inferior to surgical
repair with a reduced InH-LoS and RBC transfusion. It can be success-
fully employed even in nonelective setting. A randomized controlled trial
with long-term follow-up and appropriate patient inclusion criteria is
necessary to compare these 3 treatment options.
(Medicine 94(30):e1130)
Abbreviations: ABI = ankle-brachial index, CTA = computed
tomography angiography, GSV = great saphenous vein, InH-Los =
in-hospital length of stay, PAA = popliteal artery aneurysm, RBC =
red blood cell.
INTRODUCTION
S urgical bypass is considered the gold standard for poplitealartery aneurysm (PAA) repair, especially in young patients
fit for conventional surgery.1 The great saphenous vein (GSV) is
the ideal conduit and the prosthetic grafts a valid alternative to
GSV for surgical bypass.2 Since the first endovascular treatment
reported by Marin et al,3 a valuable increase in papers reporting
on outcomes with this approach has emerged.4 This less inva-
sive treatment allows the PAA exclusion also in patients
considered unfit for conventional surgery. Mid and long-term
results after PAA endovascular treatment are lacking. The aim
of this study was to compare mid-term outcomes of endovas-
cular treatment, GSV bypass and prosthetic bypass for PAA
treatment in a single-center experience.
METHODS
From 2000 to 2013 data from patients treated for PAA
were prospectively collected and retrospectively analyzed in
January 2015. PAA endovascular treatment was introduced in
our institution in 2000. All patients undergoing PAA endo-
vascular treatment were included in the study. Control patients
included more recent cases treated with GSV bypass and
prosthetic bypass. Informed consent for the procedure was
obtained from all patients and the study design was approved
by Institutional Review Boards. Indications for PAA treatment
were diameter> 20mm or PAA related symptoms. For surgi-
cal PAA repair, the first option was GSV bypass; prosthetic
grafts were employed when the GSV was not available/
inadequate or in case of posterior access and for a very short
bypass. Endovascular approach was employed in patients
considered at high risk for conventional surgery at the begin-
ning of our experience; from 2010 when the GSV was not
available and if the anatomy was favorable for an endovascular
treatment. The presence of proximal and distal landing zone
of at least 1.5 cm was present in all endovascular procedures.
In all cases, at least one run-off vessel was present before
operation. All the included patients underwent a preoperative
computed tomography angiography (CTA) (Figure 1). Patients
were divided into 3 groups according to the treatment option:
endovascular treatment (group A); femoro-popliteal bypass
with GSV (group B); and femoro-popliteal bypass with pros-
thetic graft (group C). Heterogeneity between the 3 treatment
groups was tested. Patients considered at high risk for con-
ventional surgery and anatomically unsuitable for endovas-
cular treatment were excluded from the study and treated by
best medical treatment. Femoral artery aneurysm, posttrau-
matic PAA, and popliteal artery pseudoaneurysm were also
excluded.
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Endovascular Technique
All endovascular procedures were performed in an operat-
ing room equipped with digital fluoroscopic C-arm (Euroampli
ALIEN, Eurocolumbus, Italy) to allow a prompt conversion to
open surgery if necessary. A vascular surgeon performed all
procedures under general (5) or local anesthesia (20). In 17
cases access to PAAwas omolater through a femoral cut-down;
in the remaining 8 cases PAA was accessed percutaneously
though the contralateral femoral artery. Aweight-adjusted bolus
of heparin was administrated intravenously and an intraopera-
tive angiogram was performed to confirm the PAA location. In
all cases the Viabahn Endoprosthesis (Gore, Flagstaff, Arizona)
was employed to exclude the PAA. Stent-grafts were deployed
with a minimum of 1.5 cm of proximal and distal landing zone
(Figure 2). Stent-grafts size was chosen with 1mm oversizing.
A mean of 1.44 (r: 1–3; SD: 0.7) stent-grafts per patient was
employed. A preoperative fibrinolysis was employed in 4 (16%)
patients due to acute PAA thrombosis. A completion arterio-
graphy with knee in flection (>908) was performed to assess the
stent-graft flexibility (Figure 3). All patients underwent to dual
antiplatelet regimen for at least 1 month.
Surgical Technique
All procedures were performed under general anesthesia.
A medial approach was chosen in 12 cases: these bypasses were
performed according to the standard technique with surgical
exposure of femoral bifurcation or proximal superficial femoral
artery as inflow source. The distal popliteal artery was chosen as
distal outflow point when possible; if not available the tibio-
pernoeal trunk was the second option. For the medial approach,
the bypass conduit was an autologous GSV in 10 cases and a
prosthetic PTFE graft in 2 cases. The posterior approach was
used in 30 cases and performed with patients in prone position
using an S-shaped incision in correspondence of the popliteal
fossa. The conduit for this approach was an autologous GSV in
18 cases and a prosthetic PTFE graft in 12 (Figure 4). The PTFE
synthetic grafts employed were gelatin-coated PTFE (Vascutek
Ltd, Renfrewshire, UK) grafts in 13 cases and heparin-bonded
ePTFE (Propaten Gore-Tex; WL Gore & Associates Inc, Flag-
staff, Ariz) graft in the remaining case.
FIGURE 1. Preoperative CTA angiography three-dimensional
reconstruction showing popliteal artey aneurysm location.
CTA¼ computed tomography angiography.
FIGURE 2. A, Intraoperative frontal view arteriogram. Popliteal
artery aneurysm. B, Intraoperative frontal view arteriogram. Popli-
teal artery aneurysm exclusion after stent-graft deployment.
FIGURE 3. Intraoperative arteriogram. Lateral view with 90 joint
flexion.
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Follow-Up Protocol
All cases were followed with duplex ultrasound and
clinical examination at 1, 6, and 12 months and annually
thereafter. Endovascular cases underwent additionally to bipla-
nar X-ray imaging before discharge.
OUTCOMES
Early outcomes measured were technical success, perio-
perative mortality, and morbidity. Technical success was
defined as procedure completed as intended. Late outcomes
included survival, primary and secondary patency, and freedom
from reintervention rate. All these outcomes were analyzed for
the whole cohort and for each treatment group. Differences in
preoperative, postoperative, and during follow-up were
assessed for ankle-brachial index. In-hospital length of stay
(InH-Los), red blood cell (RBC) transfusion, and limb loss were
reported. Limb loss was defined as major amputation above or
below the knee. Mean follow-up was 49 (median 35; 1–145; SD
42) months.
Statistical Analysis
Means (m), median, range (r), and standard deviation (SD)
were reported for parametric data; absolute values (n) and
percentages (%) for nonparametric data. Differences between
groups were assessed using the t test or ANOVA for parametric
data and the x2 test for categorical variable. Kaplan–Meier
curves were used to estimate survival, primary and secondary
patency, and freedom from reintervention. Differences in
curves were assessed with the Brelow test. Statistical signifi-
cance was assigned at P<0.05. Statistical analysis was per-
formed using SPSS16.0 (SPSS Inc, Chicago, IL).
RESULTS
A total of 67 nonconsecutive patients (55 males) were
included, with a mean age of 69 (median 69; r: 49–87; SD: 9)
years. According to the treatment option, 25 patients were
assigned to group A, 28 to group B, and 14 to group C.
Indication to PAA treatment was symptoms presence in 23
(34%) cases; of these 14 (61%) presented an acute PAA
symptoms onset (4 in group A; 8 in group B, and 2 in group
C; P¼0.72). Demographics and comorbidities are reported in
Table 1.5–7 Mean PAA diameter was 28 (median: 26; r: 22–54;
SD: 8) mm with no significant differences between groups (24
vs. 27 vs. 26; P¼0.26). In the group A mean diameter at
proximal and distal landing zone was 5.4 (SD: 2) mm and 4.5
(SD: 1) mm, respectively. The heterogeneity test with multiple
comparisons between the 3 groups showed a significant differ-
ence in the age variable for group A versus B (P¼0.002); and
in chronic obstructive pulmonary disease for group A versus B
(P¼0.026) and for group A versus C (P¼0.010). All other
examined parameters, including acute onset of symptoms and
preoperative run off vessels, showed no significant differences
(Table 1). Mean preoperative ABI was 0.72 (median: 0.6; SD:
0.3); no statistical significant differences were observed
between groups A, B, and C (0.69 vs. 0.72 vs. 0.73; P¼0.10).
In 16 patients a preoperative intra-arterial thrombolysis
was employed before PAA treatment, in 4 cases of the group A,
in 10 of the group B, and in 2 of the group C. The intra-arterial
thrombolysis was used for all acute symptomatic PAA (14/14;
100%) patients and in 2 nonacute symptomatic (2/23; 9%) PAA
patients of the group B.
Technical success was achieved in all cases. No perio-
perative death occurred in all groups. Overall 3 (4.5%) perio-
perative complications were observed in 3 patients: 1 (4%)
patient in group A presented to inguinal hematoma; 1 (4%) in
group B and 1 (7%) in group C had a wound bleeding requiring
surgical hemostasis. No significant difference in complication
rate was observed between the 3 groups (P¼0.866). Mean
postoperative ABI was 0.89 (median: 0.9; SD: 0.15); between
groups a statistical difference in favor of group A was observed
in comparison to group B and C (0.95 vs. 0.85 and 70.9;
P¼0.022).
Overall, 5 years estimated survival was 78% (Figure 5A).
During follow-up overall graft thrombosis occurred in 14 (21%)
patients: 5 (20%) occlusion in group A; 5 (19%) in group B, and
4 (29%) in group C. No significant difference in occlusion
incidence between the 3 groups (P¼0.726) was observed
during the follow-up. No stent-graft fracture was observed in
group A. Mean interval time to thrombosis was 18 (median: 6; r:
0–73; SD: 21) months.
Estimated 5-years primary patency for groups A, B, and C
was 71%, 81%, and 69%, respectively, with no statistical
differences between the 3 treatment groups (P¼0.19)
(Figure 5B). Estimated 5-years secondary patency for groups
A, B, and C was 88%, 85%, and 84% with no statistical
differences between curves (P¼0.85) (Figure 5C). During
the follow-up all secondary interventions were occlusion-
related. These were necessary in 12 of the 14 occlusions; 4
were performed in group A, 5 in group B, and 3 in group C. No
statistical significant differences were observed in reinterven-
tion rate between the 3 groups (P¼0.918). The remaining 2
patients presenting a graft thrombosis underwent to limb ampu-
tation for irreversible ischemia and medical therapy for an
asymptomatic occlusion. Estimated 5-years freedom from rein-
tervention for groups A, B, and C was 62%, 84%, and 70%,
respectively, with no statistical differences between curves
(P¼0.16) (Figure 5D). At mean follow-up ABI was 0.87
(median: 0.9; SD: 0.16) and no statistical significant differences
were observed between groups A, B, and C (0.82 vs. 0.75 vs.
0.79; P¼0.13). Overall a significant difference was observed
between preoperative ABI versus postoperative ABI
(P¼0.001), and preoperative ABI versus follow-up ABI
(P¼0.003). No differences were observed between postopera-
tive ABI versus follow-up ABI (P¼0.18)
Mean InH-LoS was 6.5 (median: 7; r: 2–14; SD: 3) days.
InH-Los was 4.1 (median: 4; SD: 1) days, 7.9 (median: 8; SD: 2)
days, and 8.01 (median: 8; SD: 2) days for groups A, B, and C,
respectively; the multiple comparisons between the 3 groups
showed a significant difference InH-LoS for group A versus B
FIGURE 4. Intraoperative view of a short great saphenous vein
bypass with posterior approach.
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(P<0.001) and for group A versus C (P<0.001). RBC
transfusion was required in 1, 6, and 4 patients in groups A,
B, and C, respectively; the multiple comparison between the 3
groups showed a significant difference in RBC transfusion for
group A versus group C (P¼0.045). Overall limb salvage was
achieved in all but 1 patient presenting symptoms. During
follow-up this patient from group B underwent to below the
knee amputation after 2 years due to bypass occlusion. No limb
loss was observed in patients presenting asymptomatic PAA.
DISCUSSION
PAAs are the most common peripheral aneurysms with a
reported incidence of 0.1–3%. In asymptomatic patients, to
prevent potential complications, the reported indications to
PAA repair are size >20 mm, high-grade thrombus and poor
run-off vessels. PAA symptoms represent an absolute indication
to repair.8,9 Some authors justify an aggressive PAA manage-
ment for size less than 20 mm due to a reported amputation rate
of 30% after PAA acute thrombosis.10 Also compartment
syndrome and peripheral embolization are PAA complications
with an increased limb loss risk leading, infrequently, to
death.11–14 Also PAA rupture is rare and 50–75% of these
cases present with pain and swelling in the popliteal fossa and
symptoms of lower extremity ischemia.15 In the present series
PAA symptoms were the indication to repair in 34% of cases; 6
(26%) of these 23 patients were in group A.
PAA instrumental diagnosis is easily achieved with duplex
ultrasound (DUS) test that can differentiate PAA from other
popliteal fossa pathologies such us Baker cysts or tumors.
Computed tomographic angiography (CTA), magnetic reson-
ance angiography, and/or invasive arteriography are necessary
to plan an endovascular treatment.16 In all cases PAA diagnosis
was achieved with DUS. In group A, patients underwent
additionally to CTA in order to assess PAA anatomical findings
and the feasibility of endovascular treatment.
PAA surgical treatment is burdened by a relatively low
perioperative mortality rate of 0–1% in asymptomatic patients
and about 2% in symptomatic cases; conversely, a high peri-
operative morbidity mainly related to access complications is
reported ranging from 30% to 40%.17 The PAA endovascular
treatment has shown excellent perioperative outcomes in terms
of mortality and morbidity.18 Potential complication of endo-
vascular treatment, such as endograft fracture, endoleak, or
migration, has been rarely reported.19–22
The endovascular approach was introduced as an alterna-
tive in patients unfit for conventional surgery. Galinanes et al
have reported the increase of this less invasive intervention after
10 years from its introduction. In this review of the Centers for
Medicare and Medicaid inpatient claims between 2005 and
2007, endovascular interventions have significantly increased
(11.7% vs. 23.6%, P<0.0001).23 Despite this, the small-size
long-term results, the limited experience reported, and the
reduced patency rate have been considered limitations of this
technique.24
The use of Haemobahn/Viabahn stent-graft (W.L. Gore &
Associates Inc., Flagstaff, AZ, USA) has been advocated as first
option stent-graft due to the PTFE cover and the relative
TABLE 1. Heterogeneity Test for Demographics and Comor-
bidities by Groups
Median age, yrs 69 7 P.008
Group A 71 6
Group B 66 10
Group C 68 7
Hypertension 63 (94%) P.58
Group A 23 (92%)
Group B 26 (92%)
Group C 14 (100%)
Smoking 39 (58%) P.81
Group A 14 (60%)
Group B 15 (53%)
Group C 9 (64%)
Coronary artery disease 28 (42%) P.41
Group A 10 (40%)
Group B 14 (50%)
Group C 4 (28%)
Lipid disorder 26 (39%) P.08
Group A 10 (36%)
Group B 14 (29%)
Group C 4 (64%)
Diabetes mellitus 20 (30%) P.93
Group A 7 (28%)
Group B 9 (32%)
Group C 4 (29%)
COPD 17 (25%) P.018
Group A 11 (44%)
Group B 5 (17%)
Group C 1 (7%)
Renal function impairment 14 (21%) P.06
Group A 9 (36%)
Group B 4 (14%)
Group C 1 (7%)
Contralateral PAA 34 (51%) P.77
Group A 13 (54%)
Group B 13 (46%)
Group C 8 (57%)
Associated abdominal aneurysm 28 (42%) P.18
Group A 12 (46%)
Group B 12 (29%)
Group C 8 (57%)
Symptoms 23 (34%) P.36
Acute onset 14 (21%) P.72
Group A 6 (24%)
Acute onset 4 (16%)
Group B 12 (43%)
Acute onset 8 (29%)
Group C 5 (36%)
Acute onset 2 (14%)
Run-off vessels at arrival (mean) 2.1 P. 11
Group A 2.2
Group B 1.8
Group C 2.3
Preoperative run-off vessels
before intervention (mean)
2.5 P. 41
Group A 2.4
Group B 2.3
Group C 2.6
Comorbidities were defined according to the Ad Hoc Committee for
Standardized Reporting Practices in Vascular Surgery of the Society for
Vascular Surgery5 and the American Association for Vascular Surgery
and the National Kidney Foundation.6 Abdominal aortic aneurysm was
defined according to the reporting standards for endovascular aortic
aneurysm repair.7 COPD¼ chronic obstructive pulmonary disease;
PAA¼ popliteal artery aneurysm.
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flexibility in order to increase patency outcomes. However,
diameter discrepancy from proximal to distal landing zone
represents a relevant limitation of this device.25
Also anatomic features of popliteal artery with regards to
physiological knee movements determining artery morphologi-
cal changes and stent stress represent adjunctive limitations for
a stent implantation. These morphological alterations are
deemed responsible for the reduced patency rate after stent
placement, which is the Achilles tendon of PAA endovascular
treatment.26 The use of a contralateral access in percutaneous
endovascular PAA repair was chosen to reduce access site
complication risk. In fact, the use of large introducer in an
antegrade fashion has been related to an increased risk of
femoral access complication. When a percutaneous contralat-
eral access was not feasible due to anatomic limitations (such as
angulated aorta or iliac stenosis), an omolateral femoral cut-
down was employed. For surgical treatment, the bypass conduit
choice has been historically related to patency outcomes. In a
Mayo Clinic study of 385 surgical PAA treatments, the 5-year
primary and secondary patency rates were 76% and 87%,
respectively; these outcomes were significantly better with
GSV (85% and 94%) when compared to PTFE prosthetic graft
(50% and 63%) (P<0.05).27 Similar results have been reported
with the posterior approach.9 In the present series, we did not
observe a significant difference in the 5-years primary and
secondary patency outcomes between GSV and PTFE prosthe-
tic graft. Piazza et al, in a single-center experience with
endovascular repair of 47 PAA, report a 5-year primary and
secondary patency of 76% and 82%, respectively.28 These
results are comparable with those reported in the present study
with a 5-years primary and secondary patency of 69% and 84%,
respectively, after endovascular repair. During last few years,
no inferior results have been reported of endovascular PAA
repair when compared to bypass surgery in terms of patency.29
We have not found significant differences between the 3
treatment groups in terms of primary and secondary patency,
but a tendency for better primary patency outcomes in group B
of GVS bypass. In a retrospective multicentric study on 312
PAAs, also Pulli et al reported no significant differences
between open (178 PAAs) and endovascular (134 PAAs) repair
in terms of primary and secondary patency.18 The primary
patency outcome was clinically reflected by the ABI result:
overall ABI analysis reported a significant improvement from
preoperative to postoperative stage. This advantage was durable
at follow-up analysis. However, a nonsignificant slight decrease
in ABI values was observed in group A from postoperative to
follow-up stage in accordance with the nonsignificant decrease
in patency outcome.
As already reported,17 a significant advantage in terms of
InH-LoS is evident with an endovascular approach; moreover,
we have also found a significant advantage also in terms of
RBC transfusions.
Patient age has been related to popliteal artery tortuosity
with an increasing degree proportional to age,30 especially in the
FIGURE 5. A, Overall cumulative survival. Standard error (SE) did not exceed 10% at 60-month follow-up (SE¼8% at 60 months). B,
Primary patency. SE did not exceed 10% at 60-month follow-up for group B (SE¼9% at 60 months). SE exceed 10% at 12 months in
group A (SE¼12% at 60 months) and C (SE¼13% at 60 months). C, Secondary patency. SE did not exceed 10% at 60-month follow-up
for group B (SE¼8% at 60 months). SE exceed 10% at 26 months in group A (SE¼12% at 60 months) and at 37 months in group C
(SE¼10% at 60 months). D, Freedom from reintervention. SE did not exceed 10% at 60-month follow-up for group B (SE¼9% at 60
months). SE exceed 10% at 12 months in group A (SE¼16% at 60 months) and C (SE¼13% at 60 months).
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supra-genicular segment.17 Despite this, and according to most
authors recommendations,31 we have used the endovascular
approach in older patients unfit for conventional PAA vein bypass
treatment. A recent decision analysis study, with Markov model,
suggests that GSV bypass is still the PAA treatment gold stan-
dard. Patients with short life expectancy or with advanced age
should undergo to conservative management. Thus, endovascular
approach is indicated for high-risk patients not suitable for open
repair and for patients without a suitable autologous vein.1 Also,
our PAA protocol provided the GSV bypass as first line approach
and the prosthetic bypass as a second option. However, from
2010, a shift toward the endovascular PAA repair as second-
option treatment from the prosthetic bypass was observed. The
lack of guidelines32 and evidences to advocate a change in the
PAA ‘‘gold standard’’ surgical treatment1 is evident. A random-
ized controlled trial with a large homogeneous population is
awaited.33 In our experience patients treated endovascularly were
significant elderly, with higher rate of COPD and there was
tendency of worst renal function. Despite this, the endovascular
treatment was not inferior in terms of early outcomes (technical
success, perioperative mortality, and morbidity) and mid-term
outcomes (survival, primary and secondary patency, and freedom
from reintervention rate) when compared to surgical options, but
a reduced InH-Los and RBC transfusion were reported.
Limitations of this study are the lack of randomization, the
retrospective analysis, and the inclusion criteria of the control
groups. Moreover to the lack of significant difference for
outcomes such as primary patency can be related to the relative
small patient sample.
CONCLUSION
PAA repair is safe with good early and long-term results
independently from the treatment option adopted. The endo-
vascular treatment has anatomic limitations related to popliteal
artery movements but is not inferior to surgical prosthetic graft
repair. This approach has a reduced InH-LoS and RBC transfu-
sion and it can be successfully employed in nonelective setting.
The GSV has nonsignificantly better outcomes in comparison to
prosthetic graft. A randomized controlled trial with long-term
follow-up and appropriate patient inclusion criteria is necessary
to compare the 3 treatment options.
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